About Novavax, Inc.
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.
2BB score and signals
Novavax, Inc.’s current 2BB score is 42 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 32 | Low |
| Momentum | 88 | Strongly Improving |
| Financial strength | 14 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 49 | Moderate |
Company facts
| CEO | John C. Jacobs |
| Headquarters | Gaithersburg, Maryland, United States |
| Founded | 1987 |
| Employees | 749 |
| 52-week range | $6.20 – $11.97 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-24 | — | -0.1067 | — | $95.70M |
| 2026-11-04 | — | -0.2368 | — | $74.11M |
| 2026-08-06 | — | -0.4137 | — | $52.12M |
| 2026-05-06 | -0.06 | -0.2349 | $139.51M | $79.89M |
Related companies
